⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7998742 | 0.80 | — | — | |
| SCHEMBL696929 | 0.75 | KMT2A (0.37) | — | |
| SCHEMBL126519 | 0.65 | — | — | |
| SCHEMBL20563637 | 0.65 | GABRA1 (0.39) | — | |
| SCHEMBL2624390 | 0.63 | CCNE1 (0.30) | — | |
| SCHEMBL2039242 | 0.59 | — | — | |
| SCHEMBL183565 | 0.59 | — | — | |
| SCHEMBL385899 | 0.59 | — | — | |
| SCHEMBL9215009 | 0.59 | — | — | |
| SCHEMBL14074679 | 0.56 | ALOX5 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023070120-A1 | KETOAMIDES FOR TREATING MALIGNANCY | BIOTHERYX, INC. (US) | 2023-04-27 | — | — | WO | claimed |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | claimed |
| CN-114502543-A | Targeted protein compounds, pharmaceutical compositions and therapeutic applications thereof | 拜欧斯瑞克斯公司 | 2022-05-13 | — | — | CN | claimed |
| WO-2020242960-A1 | COMPOUNDS TARGETING PROTEINS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2020-12-03 | — | — | WO | claimed |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2020-11-26 | — | — | US | claimed |
| WO-2005005382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-01-20 | — | — | WO | claimed |
| EP-4393965-A1 | BRANCHED PROPYLENE-BASED POLYMER | Japan Polypropylene Corporation (JP) | 2024-07-03 | — | — | EP | disclosed |
| CN-115702174-B | Production of polypropylene with low volatiles | 博里利斯股份公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4298098-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2024-01-03 | — | — | EP | disclosed |
| CN-115315451-B | Catalyst for olefin polymerization, method for producing catalyst for olefin polymerization, and method for producing olefin polymer using catalyst for olefin polymerization | 日本聚丙烯株式会社 | 2023-12-01 | — | — | CN | disclosed |
| CN-114616280-B | Heterophasic propylene ethylene copolymer compositions with desirable balance of mechanical properties | 北欧化工公司 | 2023-10-13 | — | — | CN | disclosed |
| US-11643485-B2 | Ethylene-based polymer, polyethylene-based resin composition and use thereof, catalyst component for olefin polymerization, olefin polymerization catalyst containing the component, and method for producing ethylene-based polymer by using the catalyst | JAPAN POLYETHYLENE CORPORATION (JP) | 2023-05-09 | — | — | US | disclosed |
| WO-2023070120-A1 | KETOAMIDES FOR TREATING MALIGNANCY | BIOTHERYX, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005005382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-5681961-A | TREATMENT AND/OR PREVENTION OF THROMBOEMBOLIC DISORDERS, ARTERIOSCLEROSIS, METASTASIS. ISCHEMIA, ASTHMA, ALLERGIES | DR. KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| US-5426119-A | Thromboxane antagonists | DR. KARL THOMAE GMBH (DE) | 1995-06-20 | — | — | US | disclosed |
| US-5294626-A | Thromboxane synthesis inhibitors and anticoagulants | DR. KARL THOMAS GMBH (DE) | 1994-03-15 | — | — | US | disclosed |
| EP-0399267-A2 | 8-Substituted-4-(heterocyclylmethylamino)-quinolines, their use and drugs prepared from them | BASF Aktiengesellschaft (DE) | 1990-11-28 | — | — | EP | disclosed |